March 2, 2026
TOPLINE: MRI-guided personalisation of neoadjuvant chemotherapy duration was associated with favourable 3-year event-free survival outcomes of more than 92% in patients with stage II-III HER2-positive breast […]
February 27, 2026
TOPLINE: Exercise interventions — including aerobic exercise, combined aerobic-strength training, and strength training — were associated with improved quality of life (QoL) in women with breast […]
February 27, 2026
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a conditional marketing authorization for a new medicine to treat pediatric […]
February 27, 2026
When Chad Mirkin, PhD, asked his graduate students to run a “Friday afternoon experiment” nearly 20 years ago, he wasn’t expecting to affect cancer treatment. He […]
February 27, 2026
The FDA has granted zongertinib (HERNEXEOS, Boehringer Ingelheim Pharmaceuticals, Inc.) a first-line indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose […]
February 26, 2026
Risk-reducing bilateral mastectomy dramatically lowers the risk for breast cancer compared with surveillance among BRCA1/2 mutation carriers, but whether that benefit extends to improved survival remains […]
February 26, 2026
Multicancer blood tests have for years been hyped as a potential breakthrough in early cancer detection. But with news that one of the big names in […]
February 26, 2026
Can agnostic therapies revolutionize precision oncology? Are we ready to treat cancer without looking at the organ? For decades, cancer has been told as a story […]
February 25, 2026
The FDA has granted traditional approval to encorafenib (Braftovi, Pfizer) in combination with cetuximab (Erbitux, Eli Lilly) and fluorouracil-based chemotherapy for treatment of adults with metastatic […]